Ulf Grawunder is founder and CEO of NBE-Therapeutics, a Swiss Biotech company incorporated in 2012, which focuses on the development of "next-generation" antibody-drug conjugates for cancer therapy.
Prior to that, Ulf had co-founded 4-Antibody in 2004, a Swiss therapeutic antibody engineering company, where he initially served as CEO and later as CSO, until the company was sold to US-based Agenus in 2013. Ulf is a Biochemist who did his PhD in area of B cell Immunology at the Basel Institute for Immunology. After this he did several years of post-doctoral research at Washington University School of Medicine, St. Louis, and the University of Southern California, Los Angeles, and continued as principal investigator again at the Basel Institute for Immunology, and the University of Basel, Switzerland, before he started his first Biotech company.
Ulf is member of a number of national and international boards of for profit and non-profit organizations, including the scientific advisory board of the Bavarian Immunotherapies Network, BayImmuNet, Germany (www.bayimmunet.de), and the Board of the Swiss Biotech Association (SBA, www.swissbiotech.org).